Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
复制标题
DOI:
10.1016/j.ccr.2010.03.008
复制
发表时间:
2010-04-13
期刊:
影响因子:
50.3
通讯作者:
Marcucci G
中科院分区:
文献类型:
--
作者:
Liu S;Wu LC;Pang J;Santhanam R;Schwind S;Wu YZ;Hickey CJ;Yu J;Becker H;Maharry K;Radmacher MD;Li C;Whitman SP;Mishra A;Stauffer N;Eiring AM;Briesewitz R;Baiocchi RA;Chan KK;Paschka P;Caligiuri MA;Byrd JC;Croce CM;Bloomfield CD;Perrotti D;Garzon R;Marcucci G
The biologic and clinical significance of KIT overexpression that associates with KIT gain-of- function mutations occurring in subsets of acute myeloid leukemia (AML) (i.e., core binding factor AML) is unknown. Here, we show that KIT mutations lead to MYC-dependent miR-29b repression and increased levels of the miR-29b target Sp1 in KIT-driven leukemia. Sp1 enhances its own expression by participating in a NFκB/HDAC complex that further represses miR-29b transcription. Upregulated Sp1 then binds NFκB and transactivates KIT. Therefore, activated KIT ultimately induces its own transcription. Our results provide evidence that the mechanisms of Sp1/NFκB/HDAC/miR-29b-dependent KIT overexpression contribute to leukemia growth and can be successfully targeted by pharmacological disruption of the Sp1/NFκB/HDAC complex or synthetic miR-29b treatment in KIT-driven AML.
登录
查看更多内容
DOI:
10.1073/pnas.0812413106
发表时间:
2009-02-03
影响因子:
11.1
作者:
Gajiwala, Ketan S.;Wu, Joe C.;Demetri, George D.
通讯作者:
Demetri, George D.
DOI:
10.1073/pnas.2133048100
发表时间:
2003-10-14
影响因子:
11.1
作者:
Hong, JW;Allen, CE;Wu, LC
通讯作者:
Wu, LC
影响因子:
4.5
作者:
Quinn, David I.;Nemunaitis, John;Dudov, Assen
通讯作者:
Dudov, Assen
影响因子:
5.3
作者:
Kozlowski, M;Larose, L;Siminovitch, KA
通讯作者:
Siminovitch, KA
影响因子:
56.9
作者:
PAGANO, M;TAM, SW;ROLFE, M
通讯作者:
ROLFE, M